ArticleFolia microbiologica2026
Characterization of a K62-specific phage depolymerase and its protective effect in a mouse model of Klebsiella pneumoniae infection.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multidrug-resistantKlebsiella pneumoniae has emerged as a formidable healthcare challenge, driving the urgent need for alternative therapeutic strategies such as phage therapy. In this study, we isolated and comprehensively characterized a novel phage, designated vB_Kp_IME328 (IME328), which exhibits highly specific bactericidal activity against K62-type K. pneumoniae. Morphological analyses revealed that IME328 forms plaques surrounded by distinct translucent halos and possesses a long tail, clustering it within the Webervirus genus. Through whole-genome sequencing and bioinformatic analysis, we identified ORF3 as the gene encoding a putative tail-fiber depolymerase. This gene was successfully cloned and expressed, yielding the recombinant protein Dp3. Functional assays confirmed that Dp3 possesses robust depolymerizing and antibacterial activities. In vitro, Dp3 acted synergistically with serum to effectively eradicate the target bacteria. Furthermore, live/dead cell staining and cellular assays demonstrated that Dp3 significantly enhances the phagocytic and intracellular bactericidal capacities of macrophages. In vivo evaluations using a lethal murine bacteremia model (inoculated with 6 × 10⁷ CFU) showed that Dp3 administration conferred 100% protection and survival, whereas all untreated infected mice succumbed to the infection. Together, our findings highlight the targeted anti-virulence properties of the depolymerase Dp3. By enhancing host-mediated immune clearance, Dp3 offers a promising therapeutic strategy against antibiotic-resistant K62-type K. pneumoniae infections.
Indexed as
Identifiers
42853512What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.